ChemDiv acquires Prudentas
San Diego headquartered ChemDiv, a chemistry driven contract research organisation, has acquired Prudentas through its ChemRar High Tech Centre in Moscow.
San Diego headquartered ChemDiv, a chemistry driven contract research organisation, has acquired Prudentas through its ChemRar High Tech Centre in Moscow.
Prudentas is a leading CRO company conducting Phase I - Phase IV studies in Eastern Europe. It will continue to operate separately as a ChemDiv Group company.
ChemDiv says Prudentas will add value to its Discovery outSource services business. Nikolay Savchuk, president and chief executive, said: "This acquisition is synergistic to the continued development of our Chemical Diversity Research Institute subsidiary and our other discovery services holdings such as Drugs Technology, which provides GLP/GMP formulation and CMC services.
"We believe Prudentas will help us bring unique levels of clinical development productivity to pharma and biotech partners through risk mitigation, cost- and time-savings."
The transaction also strengthens and expands ChemDiv's presence in the Eastern European and Eurasian markets.
ChemDiv covers the range of disciplines needed to bring CNS, oncology, inflammation, metabolic and infectious disease projects from identification of a biological target to clinical drug and drug development candidates.